Clin Mol Hepatol.
2023 Apr;29(2):345-348. 10.3350/cmh.2023.0094.
The prime time for management of hepatocellular carcinoma in Hong Kong
- Affiliations
-
- 1Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
- 2State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, China
- KMID: 2541413
- DOI: http://doi.org/10.3350/cmh.2023.0094
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma: Editorial on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”
- Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?”
- Personalized management of cirrhosis by non-invasive tests of liver fibrosis
- Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
- Steatotic liver disease: Know your enemies
